Use of biomarkers in the management of heart failure: Are we there yet?

Circulation

Volumn 107, Issue 9, 2003, Pages 1231-1233

  Bozkurt, Biykem ^b   Mann, Douglas L ^a  

^a Winters Ctr for Heart Failure Res   (United States)

^b NONE

Author keywords

Editorials; Heart failure; Morbidity; Mortality

Indexed keywords

BIOLOGICAL MARKER; CARVEDILOL; ENALAPRIL; IBOPAMINE; MOXONIDINE; NORADRENALIN; SPIRONOLACTONE;

CLINICAL TRIAL; DRUG EFFECT; EDITORIAL; HEALTH STATUS; HEART FAILURE; HUMAN; LABORATORY TEST; NORADRENALIN BLOOD LEVEL; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; NOREPINEPHRINE; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0037432299     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000057608.97285.20     Document Type: Editorial

References (12)

1. Anand IS, Fisher LD, Chiang Y-T, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in Val-HeFT. Circulation. 2003;107:1278-1283.
2. Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation. 1990;82:1730-1736.
3. Francis GS, Cohn JN, Johnson G, et al. Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation. 1993; 87(suppl 6):VI40-VI48.
4. Benedict CR, Francis GS, Shelton B, et al. Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. Am J Cardiol. 1995;75:1151-1157.
5. Richards AM, Doughty R, Nicholls MG, et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group Circulation. 1999;99: 786-792.
6. Hampton JR, van Veldhuisen DJ, Kleber FX, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators [see comments]. Lancet 1997;349: 971-977.
7. Cohn J. Heart failure: MOXCON (Moxonidine for Congestive Heart Failure). Circulation 1999;100:e128.
8. Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001;37(5): 1228-1233.
9. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001;37: 386-391.
10. Bettencourt P, Ferreira S, Azevedo A, et al. Preliminary data on the potential usefulness of B-type natriuretic peptide levels in predicting outcome after hospital discharge in patients with heart failure. Am J Med. 2002;113:215-219.
11. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126-1130.
12. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999;100: 1056-1064.